TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Brief Summary: Few empirically-based treatment models exist for adolescent suicide attempters post psychiatric hospitalization, despite the fact that managed care has limited the role of hospitalization to stabilization, rather than remission. This study will test the efficacy and initial outcomes of Attachment Based Family Therapy (ABFT) as an aftercare model to further gains made in inpatient treatment and reduce risk factors for future suicide attempts.


Options:
A: Arm Label: Attachment Based Family Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment Based Family Therapy | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Attachment Based Family Therapy; Assigned to Arm(s): Attachment Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Study participants; Type: EXPERIMENTAL; Interventions: Other: EMA | Intervention Type: OTHER; Name: EMA; Assigned to Arm(s): Study participants
C: Arm Label: TAU w/ mobile app + volunteer support; Type: EXPERIMENTAL; Interventions: Behavioral: Volunteer support, Other: Mobile app | Arm Label: TAU w/ mobile app engagement; Type: EXPERIMENTAL; Interventions: Other: Mobile app | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Volunteer support; Assigned to Arm(s): TAU w/ mobile app + volunteer support | Intervention Type: OTHER; Name: Mobile app; Assigned to Arm(s): TAU w/ mobile app + volunteer support, TAU w/ mobile app engagement
D: Arm Label: Inpatient Adaptation of DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Inpatient Adaptation of DBT | Arm Label: Outpatient DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: standard outpatient DBT | Intervention Type: BEHAVIORAL; Name: standard outpatient DBT; Assigned to Arm(s): Outpatient DBT | Intervention Type: BEHAVIORAL; Name: Inpatient Adaptation of DBT; Assigned to Arm(s): Inpatient Adaptation of DBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Brief Summary: Few empirically-based treatment models exist for adolescent suicide attempters post psychiatric hospitalization, despite the fact that managed care has limited the role of hospitalization to stabilization, rather than remission. This study will test the efficacy and initial outcomes of Attachment Based Family Therapy (ABFT) as an aftercare model to further gains made in inpatient treatment and reduce risk factors for future suicide attempts.


Options:
A: Arm Label: Attachment Based Family Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment Based Family Therapy | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Attachment Based Family Therapy; Assigned to Arm(s): Attachment Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Follow up | Arm Label: Usual Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Follow up; Assigned to Arm(s): Follow up
C: Arm Label: Iconic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Emotional regulation | Arm Label: Support therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Emotional regulation | Intervention Type: BEHAVIORAL; Name: Emotional regulation; Assigned to Arm(s): Iconic Therapy, Support therapy
D: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma
Brief Summary: This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the treatment of allergen-induced asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Arm Label: Reslizumab - 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab - 0.3 mg/kg, Reslizumab - 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab (MILR1444A) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab (MILR1444A); Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Eosinophilic phenotype (EOS+) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS+ Benralizumab (2 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 2 mg | Arm Label: EOS+ Benralizumab (20 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 20 mg | Arm Label: EOS+ Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Arm Label: Non-eosinophil phenotype (EOS-) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS- Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: BIOLOGICAL; Name: Benralizumab 2 mg; Assigned to Arm(s): EOS+ Benralizumab (2 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 20 mg; Assigned to Arm(s): EOS+ Benralizumab (20 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): EOS+ Benralizumab (100 mg), EOS- Benralizumab (100 mg) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Eosinophilic phenotype (EOS+) Placebo, Non-eosinophil phenotype (EOS-) Placebo
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma
Brief Summary: This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the treatment of allergen-induced asthma.


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study
Brief Summary: This study compares paclitaxel/carboplatin (PC) to PC chemotherapy followed by gefitinib for 2 weeks in patients with Non-small Cell Lung Cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations.

Expanded acronym : \[P\]aclitaxel/Ca\[r\]boplatin (PC) followed by Gef\[i\]tinib in A\[d\]vanc\[e\]d Non-small Cell Lung Cancer (NSCLC): Randomized phase II study.


Options:
A: Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): N/A
B: Arm Label: Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib, Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Gefitinib, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gefitinib, Placebo
C: Arm Label: Paclitaxel/Carboplatin/Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel/Carboplatin/Gefitinib | Arm Label: Paclitaxel/Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel/Carboplatin | Intervention Type: DRUG; Name: Paclitaxel/Carboplatin/Gefitinib; Assigned to Arm(s): Paclitaxel/Carboplatin/Gefitinib | Intervention Type: DRUG; Name: Paclitaxel/Carboplatin; Assigned to Arm(s): Paclitaxel/Carboplatin
D: Arm Label: Pemetrexed + Cisplatin + Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis.
Brief Summary: Patients of cirrhosis with portal hypertension aged 18 to 75 years who have small esophageal varices with or without red color signs and have not bled previously will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year. The primary endpoint of the study is the the proportions of patients who develop large varices (Gd 3 or Gd 4) at 1 year in each group. The secondary endpoint are survival,reduction in HVPG,change in CTP and MELD score\& adverse events.


Options:
A: Arm Label: Timolol Maleate; Type: EXPERIMENTAL; Interventions: Drug: Timolol Maleate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Timolol Maleate; Assigned to Arm(s): Timolol Maleate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
C: Arm Label: Endoscopic Variceal Ligation; Type: ACTIVE_COMPARATOR; Interventions: Device: multi band ligator for esophageal varices | Arm Label: Propranolol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propranolol | Intervention Type: DRUG; Name: Propranolol; Assigned to Arm(s): Propranolol | Intervention Type: DEVICE; Name: multi band ligator for esophageal varices; Assigned to Arm(s): Endoscopic Variceal Ligation
D: Arm Label: Carvedilol; Type: EXPERIMENTAL; Interventions: Drug: Carvedilol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Carvedilol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Pelvic Floor Muscle Training and Hypopressive Exercises in Women With Pelvic Organ Prolapse: Randomized Controlled Trial
Brief Summary: To verify if pelvic floor muscle training program and/or a hypopressive exercise program could improve women with stage II of pelvic organ prolapse, their symptoms or pelvic floor muscle strength.


Options:
A: Arm Label: IV Acetaminophen; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Acetaminophen | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen, Saline
B: Arm Label: PFMT group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Arm Label: HE + PFM group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Arm Label: HE group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercises | Intervention Type: OTHER; Name: Exercises; Assigned to Arm(s): Control, HE + PFM group, HE group, PFMT group
C: Arm Label: Nitrofurantoin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitrofurantoin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitrofurantoin; Assigned to Arm(s): Nitrofurantoin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Other: No bowel prep | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Other: Clear liquid diet and 2 Fleet's enemas | Intervention Type: OTHER; Name: No bowel prep; Assigned to Arm(s): Group A | Intervention Type: OTHER; Name: Clear liquid diet and 2 Fleet's enemas; Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome
Brief Summary: A multicenter, randomized, study will be performed to evaluate the efficacy of low dose steroid combined with mycophenolic acid (MyforticR) versus high dose steroid in inducing remission in adults with minimal change nephrotic syndrome (MCNS). One hundred and fourteen patients (CPP decision 2009-04-02-a5) will be included in this study. They will be randomly assigned to an open label treatment with either prednisone

1 mg/kg/day (arm A) or 0,5 mg/kg/day plus myforticR 1440 mg/day (arm B) for four weeks. The outcome will be compared during one-year follow up


Options:
A: Intervention Type: DRUG; Name: long term tapering of prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: standard prednisolone treatment; Assigned to Arm(s): N/A
B: Arm Label: B-Experimental; Type: EXPERIMENTAL; Interventions: Drug: acid mycophenolic (Myfortic) | Arm Label: A-Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A-Active Comparator | Intervention Type: DRUG; Name: acid mycophenolic (Myfortic); Assigned to Arm(s): B-Experimental
C: Arm Label: High dose prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: Alfacalcidol and low dose prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: Alfacalcidol | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Alfacalcidol and low dose prednisolone, High dose prednisolone | Intervention Type: DRUG; Name: Alfacalcidol; Assigned to Arm(s): Alfacalcidol and low dose prednisolone
D: Arm Label: Intervention: Prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Intervention: Prednisolone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers
Brief Summary: Anxiety and depression are often present in patients with chronic heart failure (CHF). This study aimed to evaluate the influence of anxiety and depression on the physical function, disability, and quality of life (QOL) in CHF. This study examined the effects of 8-week home-based exercise on these parameters, and investigated the correlations between these outcome changes.


Options:
A: Arm Label: Treadmill group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: Exercise groups; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: home-based exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise groups, Treadmill group, home-based exercise
B: Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Home-based exercise | Intervention Type: OTHER; Name: Home-based exercise; Assigned to Arm(s): Exercise
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Rehabilitation in institution | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Rehabilitation at home, Behavioral: Out-patient rehabilitation at the hospital | Intervention Type: BEHAVIORAL; Name: Rehabilitation in institution; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Rehabilitation at home; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Out-patient rehabilitation at the hospital; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Brief Summary: The purpose of this study is to determine the safety and efficacy of intravenous magnesium in shortening the duration of a pain crisis and to determine the health-related quality of life and short term outcomes of children treated with intravenous magnesium during an acute pain crisis.


Options:
A: Arm Label: Magnesium group; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Magnesium Sulfate | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline Placebo | Intervention Type: DRUG; Name: Intravenous Magnesium Sulfate; Assigned to Arm(s): Magnesium group | Intervention Type: DRUG; Name: Normal Saline Placebo; Assigned to Arm(s): Placebo group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid

Answer: A